Table 1.

Characteristics of 12 A. ustus isolates and in vitro susceptibility to amphotericin B, itraconazole, voriconazole, and terbinafine

Isolate no.aDate of isolation (day/mo/yr)OriginbAspergillusinfectionMIC (μg/ml)/MFC (μg/ml)c
AmBITZVCZTBF
AZN6779/12/1992BAL, case patientProven2/22/168/160.25/0.25
AZN67815/12/1992Sputum, case patientProven2/22/324/320.25/0.25
AZN68225/12/1992Autopsy, lung, caseProven2/24/168/80.5/0.5
AZN74126/1/1993Hematology ward, room2/22/328/160.5/0.5
AZN9247/5/1993Hematology ward, room2/22/324/80.5/0.5
AZN94314/7/1993Laboratory contaminant2/22/324/160.5/0.5
AZN272523/1/1995Sputum, patient in ENT departmentNo infection2/28/324/160.5/0.5
AZN329715/6/1995Feces, patient in neurology departmentNo infection2/22/324/40.5/0.5
AZN698922/9/1997Ascites, HIV+ patientNo infection2/22/322/80.5/0.5
AZN713415/12/1997Hematology ward, room2/22/324/320.5/0.5
CBS239.901990Biopsy of brain abscessProven2/21/10.25/0.250.06/0.06
A2521/2/1994Needle biopsy of lungProven2/22/324/80.5/0.5
  • a AZN numbers refer to isolates cultured at the University Hospital Nijmegen, Nijmegen, The Netherlands; isolate CBS239.90 was cultured at the University Hospital Utrecht, Utrecht, The Netherlands; isolate A252 was cultured at Hôpital Henri Mondor, Créteil, France.

  • b BAL, bronchoalveolar lavage specimen; ENT, ear-nose-throat; HIV+, human immunodeficiency virus positive.

  • c AmB, amphotericin B; ITZ, itraconazole; VCZ, voriconazole; TBF, terbinafine.